Table of Contents
Executive Summary
- 2007 - 2012 Market Dynamics
- Competitive Landscape
- Brand Overview
- Physician and Patient Perspectives: Findings of Our Primary Research
Chapter 1. Introduction
- Scope of the Report
- Survey Methodology
- Physician Demographics
- Patient Demographics
Chapter 2. Competitive Analysis
- Overview of Competitive Landscape
- Physician Perception of Key Competitors
- Physician Perception of Key Brands
- Comparative Labeling for Key Brands
- Comparative Pricing of Key Brands
- Reimbursement Issues
- Promotional Spending
- Company - Specific Trends
- Brand - Specific Trends
- Physician Perceptions of Type 2 Diabetes Brand Promotion
Chapter 3. Primary Research with Key Stakeholders
- Physicians
- Key Drivers of Prescriber Decisions
- Sources of Information
- Response to Messaging
- Perceptions of Competitors
- Perceptions of Brands
- Unmet Needs in Type 2 Diabetes
- Patients
- Key Drivers of Brand Use
- Response to Messaging
- Perceptions of Brands
- Unmet Needs in Type 2 Diabetes
- Influential Factors Driving Stakeholder Behavior
- Comparison of Brand Perception
Chapter 4. Established Competitors
- Takeda
- Strategic Overview
- Goals and Vision in Type 2 Diabetes
- Type 2 Diabetes Product Portfolio
- Current Positioning
- Market Strategy and Outlook
- Actos
- Actos Competitive Analysis
- Physicians Inform Our Analysis
- Key Brand Strategies
- Future Positioning and Outlook
- ActoPlus Met
- Commercial Overview
- Future Positioning
- Duetact
- Commercial Overview
- Future Positioning
- Alogliptin
- Development and Commercial Overview
- Competitive Analysis
- Future Positioning and Outlook
- GlaxoSmithKline
- Strategic Overview
- Goals and Vision in Type 2 Diabetes
- Type 2 Diabetes Product Portfolio
- Current Positioning
- Market Strategy and Outlook
- Avandia
- Avandia Competitive Analysis
- Physicians Inform Our Analysis
- Key Brand Strategies
- Future Positioning and Outlook
- Avandamet
- Commercial Overview
- Future Positioning
- Avaglim/Avandaryl
- Commercial Overview
- Future Positioning
- Merck
- Strategic Overview
- Goals and Vision in Type 2 Diabetes
- Type 2 Diabetes Product Portfolio
- Current Positioning
- Market Strategy and Outlook
- Januvia
- Januvia Competitive Analysis
- Physicians Inform Our Analysis
- Key Brand Strategies
- Future Positioning and Outlook
- Janumet
- Commercial Overview
- Future Positioning
- Eli Lilly
- Strategic Overview
- Goals and Vision in Metabolism
- Type 2 Diabetes Product Portfolio
- Current Positioning
- Market Strategy and Outlook
- Byetta
- Byetta Competitive Analysis
- Physicians Inform Our Analysis
- Key Brand Strategies
- Future Positioning and Outlook
- Byetta LAR
- Development and Commercial Overview
- Byetta LAR Competitive Analysis
- Future Positioning and Outlook
Chapter 5. Minor Competitors
- Novartis
- Strategic Overview
- Goals and Vision in Metabolism
- Type 2 Diabetes Product Portfolio
- Current Positioning
- Market Strategy and Outlook
- Starlix
- Commercial Overview
- Future Positioning
- Galvus
- Commercial Overview
- Future Positioning
- Sciele Pharma
- Strategic Overview
- Current Positioning and Future Outlook
- Prandin
- Commercial Overview
- Future Positioning
- Bayer
- Strategic Overview
- Goals and Vision in Metabolism
- Type 2 Diabetes Product Portfolio
- Precose
- Commercial Overview
- Future Positioning
- Pfizer
- Strategic Overview
- Goals and Vision in Type 2 Diabetes
- Type 2 Diabetes Product Portfolio
- Glyset
- Commercial Overview
- Future Positioning
- Amylin
- Strategic Overview
- Goals and Vision in Metabolism
- Type 2 Diabetes Product Portfolio
- Symlin
- Commercial Overview
- Future Positioning
- Novo Nordisk
- Strategic Overview
- Goals and Vision in Metabolism
- Type 2 Diabetes Product Portfolio
- Current Positioning
- Market Strategy and Outlook
- Victoza
- Development and Commercial Overview
- Competitive Analysis
- Future Positioning and Outlook
Chapter 6. Emerging Competitors
- AstraZeneca
- Strategic Overview
- Goals and Vision in Metabolism
- Type 2 Diabetes Product Portfolio
- Onglyza
- Development and Commercial Overview
- Competitive Analysis
- Future Positioning and Outlook
- Dapagliflozin
- Development and Commercial Overview
- Competitive Analysis
- Future Positioning and Outlook
- Dapagliflozin/Metformin
- Commercial Overview
- Future Positioning
- Bristol - Myers Squibb
- Strategic Overview
- Goals and Vision in Metabolism
- Type 2 Diabetes Product Portfolio
- Ortho - McNeil
- Strategic Overview
- Type 2 Diabetes Product Portfolio
- Current Positioning and Future Outlook
- Metaglidasen
- Commercial Overview
- Future Positioning
- Dr. Reddy' s Laboratories
- Strategic Overview
- Type 2 Diabetes Product Portfolio
- Current Positioning and Future Outlook
- Commercial Overview
- Future Positioning
- Daiichi Sankyo
- Strategic Overview
- Type 2 Diabetes Product Portfolio
- Current Positioning and Future Outlook
- Rivoglitazone
- Commercial Overview
- Future Positioning
- Sanofi - Aventis
- Strategic Overview
- Type 2 Diabetes Product Portfolio
- Current Positioning and Future Outlook
- Lixisenatide (AVE - 0010)
- Commercial Overview
- Future Positioning
- Boehringer Ingelheim
- Strategic Overview
- Type 2 Diabetes Product Portfolio
- Current Positioning and Future Outlook
- Commercial Overview
- Future Positioning
- Isis Pharmaceuticals
- Strategic Overview
- Type 2 Diabetes Product Portfolio
- Current Positioning and Future Outlook
- Commercial Overview
- Future Positioning
Chapter 7. Market Forecast
- Type 2 Diabetes Market Analysis
- Sales by Region
- United States
- Europe
- Japan
- Sales by Class
- Sales by Brand
- Sales by Company
Appendices
- Epidemiology
- Prevalence and Diagnosis
- Major Market Statistics and Key Findings
- Abbreviations Used in this Report
- Bibliography
- Methodology
- Epidemiology
- Market Forecast
- Emerging Therapy Prices
- Companies Included in Competitive Analysis
- Revenue Allocation
Table of Exhibits
- Executive Summary
- Exhibit 1: Key Parameters of the Type 2 Diabetes Market
- Exhibit 2: Type 2 Diabetes Branded Market, ($US), Major Markets, 2007 -
2012
- Exhibit 3: Type 2 Diabetes Market Competitive Position, 2007 and 2012
- Exhibit 4: Type 2 Diabetes Market, by Company, as a Percentage of Total,
2007 and 2012
- Exhibit 5: Type 2 Diabetes Brand Sales ($US), by Brand, as a Percentage of
Total Brand Market Sales, 2007 and 2012
- Exhibit 6: Physician Rankings of Companies in Type 2 Diabetes Treatment
- Exhibit 7: PCP and Endocrinologist Rankings of Competitors in the Branded
Type 2 Diabetes Drug Market, Based on Company Attributes
- Exhibit 8: Patients' Top - of - Mind Type 2 Diabetes Agents
- Exhibit 9: Surveyed Physicians' Years of Practice
- Exhibit 10: Surveyed Physicians' Type 2 Diabetes Patients Treated per Month
- Exhibit 11: Surveyed Physicians' Geographic Distribution
- Exhibit 12: Surveyed Patients' Age
- Exhibit 13: Surveyed Patients' Gender
- Exhibit 14: Surveyed Patients' Years Receiving Treatment for Type 2
Diabetes
- Exhibit 15: Surveyed Patients' Severity of Type 2 Diabetes
- Exhibit 16: Surveyed Patients' Healthcare Providers
- Exhibit 17: Branded Type 2 Diabetes Agents Available in 2008
- Exhibit 18: Type 2 Diabetes Sales ($MM), by Country, 2007
- Exhibit 19: Type 2 Diabetes Market Share, by Company, 2007 and 2012
- Exhibit 20: Type 2 Diabetes Major - Market Sales ($US), by Company and
Brand, 2007 - 2012
- Exhibit 21: Physicians' Top - of - Mind Companies in the Branded Type 2
Diabetes Drug Market
- Exhibit 22: Physician Rankings of the Reputation of Competitors in the
Branded Type 2 Diabetes Drug Market
- Exhibit 23: Relative Importance of Company Attributes to Physicians
- Exhibit 24. Physician Ranking of Factors that Are Most Influential in the
Decision to Use a Specific Drug
- Exhibit 25: Physicians Overall Ranking of Companies According to Specific
Attributes (Top Seven Ranked Companies)
- Exhibit 26: Physicians Overall Ranking of Companies According to Specific
Attributes (Bottom Seven Ranked Companies)
- Exhibit 27: Physicians' Overall Ranking of Companies According to Specific
Attributes (Top Seven Ranked Companies), by Physician Type
- Exhibit 28: Percentage of Surveyed Physicians Who Identify Type 2 Diabetes
Brands as Their Top - of - Mind Brand
- Exhibit 29: Physicians' Familiarity with Type 2 Diabetes Brands
- Exhibit 30: Percentage of Physicians Prescribing Type 2 Diabetes Brands in
Each Line of Therapy
- Exhibit 31: Physician Rating of Marketed Type 2 Diabetes Therapies on
Various Efficacy, Safety/Side - Effect, Convenience, and Cost End Points
- Exhibit 32. Physician Ranking of the Five Most Important Factors that
Influence the Decision to Use a PPAR - Gamma Agonist
- Exhibit 33. Physician Ranking of the Five Most Important Factors that
Influence the Choice to Use a DPP - IV Inhibitor Rather than a GLP - 1 Analogue
- Exhibit 34. Physician Rating of Marketed Type 2 Diabetes Therapies on
Efficacy, Safety, and Convenience Factors on a Scale of 1 - 10
- Exhibit 35. Physician Ranking of the Five Most Important Factors that
Influence the Choice to Use One Meglitinide Over Another
- Exhibit 36. Physician Ranking of the Five Most Important Factors that
Influence the Choice to Use One Alpha Glucosidase Inhibitor over Another
- Exhibit 37. Physician Rating of FDCs on Safety and Convenience Factors on
a Scale of 1 - 10
- Exhibit 38: Physician Ranking of the Five Most Important Factors That
Affect the Decision to Use one FDC over Another in Type 2 Diabetes
- Exhibit 39: Label Indications for Key Type 2 Diabetes Brands
- Exhibit 40: Label Comparison Among Key Brands
- Exhibit 41: Current Price per Day ($US), Key Brands, 2007
- Exhibit 42: U.S. Formulary Status of Leading Type 2 Diabetes Drugs
- Exhibit 43: Surveyed Patients' Primary Prescription Drug Coverage
- Exhibit 44: Surveyed Patients' Payment for One Month Supply
- Exhibit 45: Percentage of Total Promotional Spend for Type 2 Diabetes
Therapies, by Company, 2007
- Exhibit 46: Promotional Spend for Type 2 Diabetes Therapies, by Brand, 2007
- Exhibit 47: Promotional Spending, by Competitor, as a Percentage of Total
Spending for Agents in Type 2 Diabetes, 2005 - 2007
- Exhibit 48: Physician Perception of the Type 2 Diabetes Brand with the
Most Promotional Material
- Exhibit 49: Preferred Information Sources for Physicians Who Treat Type 2
Diabetes
- Exhibit 50: Physicians' Top Channels to Gain Information About Type 2
Diabetes
- Exhibit 51: Physician Response to Marketing Messages for a Hypothetical
Type 2 Diabetes Brand
- Exhibit 52: Physician Perception of Most Influential Branded - Drug
Messaging in the Type 2 Diabetes Market
- Exhibit 53: Physician Rankings of Type 2 Diabetes Competitors
- Exhibit 54: Physician Ranking of the Top Seven Companies According to
Specific Attributes
- Exhibit 55: Physician Ranking of the Bottom Six Companies According to
Specific Attributes
- Exhibit 56: PCP Rankings of Top Seven Companies
- Exhibit 57: Endocrinologists Ranking of Top Seven Companies
- Exhibit 58: Physician Ranking of Activities That Have the Greatest Impact
on Their Willingness to Prescribe a Brand Once the Brand Is Approved
- Exhibit 59: Number of Months After Launch Physicians Prescribe a New Agent
- Exhibit 60: Anticipated Change in the Use of Type 2 Diabetes Agents Over
the Coming Year
- Exhibit 61: Physicians' Perceptions of Future Events' Impact on the Type 2
Diabetes Market, 2009 - 2012
- Exhibit 62: Physician Awareness of Emerging Therapies
- Exhibit 63: Physician Perceptions of Unmet Needs in Type 2 Diabetes
- Exhibit 64: Patients' Most - Trusted Sources for Type 2 Diabetes Drug
Information
- Exhibit 65: Sources for Type 2 Diabetes Drug Information Used By Patients
in the Past Three Months
- Exhibit 66: Patients' Response to Marketing Messages for a Type 2 Diabetes
Drug, Using Hypothetical "Brand X"
- Exhibit 67: Patients' Perception of Influential Messaging of Type 2
Diabetes Brands
- Exhibit 68: Patients' Top - of - Mind Type 2 Diabetes Agents
- Exhibit 69: Type 2 Diabetes Agents Specifically Requested by Patients
- Exhibit 70: Current and Previous of Type 2 Diabetes Agents Taken by
Patients
- Exhibit 71: Treatment - Experienced Patients' Perceptions of the Efficacy
and Tolerability of Type 2 Diabetes Agents
- Exhibit 72: Decision to Stop Taking Type 2 Diabetes Agents
- Exhibit 73: Percentages of Patients Reporting on the Type of Support
Programs Offered
- Exhibit 74: Support Patients Would Like in the Future to Assist in the
Management of Type 2 Diabetes
- Exhibit 75: Patient Perceptions of Unmet Needs in Type 2 Diabetes
Management
- Exhibit 76: Summary of Takeda' s Type 2 Diabetes Product Portfolio
- Exhibit 77: Physician Perceptions of Takeda in Type 2 Diabetes
- Exhibit 78: Physician Perceptions of Actos
- Exhibit 79: Ongoing Clinical Trials for Actos
- Exhibit 80: Actos Revenue ($US), 2007 - 2012
- Exhibit 81: Actos Revenue ($US), by Country, 2007 - 2012
- Exhibit 82: Actoplus Met Revenue ($US), 2007 - 2012
- Exhibit 83: Actoplus Met Revenue ($US), by Country, 2007 - 2012
- Exhibit 84: Duetact Revenue ($US), 2007 - 2012
- Exhibit 85: Duetact Revenue ($US), by Country, 2007 - 2012
- Exhibit 86: Physician Perceptions of Alogliptin
- Exhibit 87: Alogliptin Revenue ($US), 2007 - 2012
- Exhibit 88: Expected Alogliptin Revenue ($US), by Country, 2007 - 2012
- Exhibit 89: Alogliptin, Expected Price per Day ($US), by Country
- Exhibit 90: Summary of GlaxoSmithKline' s Type 2 Diabetes Product Portfolio
- Exhibit 91: Physician Perceptions of GlaxoSmithKline in Type 2 Diabetes
- Exhibit 92: Physician Perceptions of Avandia
- Exhibit 93: Ongoing Clinical Trials for Avandia
- Exhibit 94: Avandia Revenue ($US), 2007 - 2012
- Exhibit 95: Avandia Revenue ($US), by Country, 2007 - 2012
- Exhibit 96: Avandamet Revenue ($US), 2007 - 2012
- Exhibit 97: Avandamet Revenue ($US), by Country, 2007 - 2012
- Exhibit 98: Avandaryl Revenue ($US), 2007 - 2012
- Exhibit 99: Avandaryl Revenue ($US), by Country, 2007 - 2012
- Exhibit 100: Summary of Merck' s Type 2 Diabetes Product Portfolio
- Exhibit 101: Physician Perceptions of Merck in Type 2 Diabetes
- Exhibit 102: Physician Perceptions of Januvia
- Exhibit 103: Ongoing Clinical Trials for Januvia
- Exhibit 104: Januvia Revenue ($US), 2007 - 2012
- Exhibit 105: Januvia Revenue ($US), by Country, 2007 - 2012
- Exhibit 106: Janumet Revenue ($US), 2007 - 2012
- Exhibit 107: Janumet Revenue ($US), by Country, 2007 - 2012
- Exhibit 108: Summary of Eli Lilly' s Type 2 Diabetes Product Portfolio
- Exhibit 109: Physician Perceptions of Eli Lilly in Type 2 Diabetes
- Exhibit 110: Physician Perceptions of Byetta
- Exhibit 111: Ongoing Clinical Trials for Byetta
- Exhibit 112: Byetta Revenue ($US), 2007 - 2012
- Exhibit 113: Byetta Revenue ($US), by Country, 2007 - 2012
- Exhibit 114: Physician Perceptions of Byetta LAR
- Exhibit 115: Byetta LAR Revenue ($US), 2007 - 2012
- Exhibit 116: Expected Byetta LAR Revenue ($US), by Country, 2007 - 2012
- Exhibit 117: Byetta LAR, Expected Price per Day ($US), by Country
- Exhibit 118: Summary of Novartis' s Type 2 Diabetes Product Portfolio
- Exhibit 119: Starlix Revenue ($US), 2007 - 2012
- Exhibit 120: Starlix Revenue ($US), by Country, 2007 - 2012
- Exhibit 121: Galvus Revenue ($US), 2007 - 2012
- Exhibit 122: Galvus Revenue ($US), by Country, 2007 - 2012
- Exhibit 123: Summary of Sciele Pharma' s Type 2 Diabetes Product Portfolio
- Exhibit 124: Prandin Revenue ($US), 2007 - 2012
- Exhibit 125: Prandin Revenue ($US), by Country, 2007 - 2012
- Exhibit 126: Summary of Bayer' s Type 2 Diabetes Product Portfolio
- Exhibit 127: Precose Revenue ($US), 2007 - 2012
- Exhibit 128: Precose Revenue ($US), by Country, 2007 - 2012
- Exhibit 129: Summary of Pfizer' s Type 2 Diabetes Product Portfolio
- Exhibit 130: Glyset Revenue ($US), 2007 - 2012
- Exhibit 131: Glyset Revenue ($US), by Country, 2007 - 2012
- Exhibit 132: Summary of Amylin' s Type 2 Diabetes Product Portfolio
- Exhibit 133: Symlin Revenue ($US), 2007 - 2012
- Exhibit 134: Symlin Revenue ($US), by Country, 2007 - 2012
- Exhibit 135: Summary of Novo Nordisk' s Type 2 Diabetes Product Portfolio
- Exhibit 136: Physician Perceptions of Novo Nordisk in Type 2 Diabetes
- Exhibit 137: Physician Perceptions of Victoza
- Exhibit 138: Victoza Revenue ($US), 2007 - 2012
- Exhibit 139: Expected Victoza Revenue ($US), by Country, 2007 - 2012
- Exhibit 140: Victoza, Expected Price per Day ($US), by Country
- Exhibit 141: Summary of AstraZeneca' s Type 2 Diabetes Product Portfolio
- Exhibit 142: Physician Perceptions of Onglyza
- Exhibit 143: Onglyza Revenue ($US), 2007 - 2012
- Exhibit 144: Expected Onglyza Revenue ($US), by Country, 2007 - 2012
- Exhibit 145: Onglyza, Expected Price per Day ($US), by Country
- Exhibit 146: Physician Perceptions of Dapagliflozin
- Exhibit 147: Dapagliflozin Revenue ($US), 2007 - 2012
- Exhibit 148: Expected Dapagliflozin Revenue ($US), by Country, 2007 - 2012
- Exhibit 149: Dapagliflozin, Expected Price per Day ($US), by Country
- Exhibit 150: Dapagliflozin/Metformin Revenue ($US), 2007 - 2012
- Exhibit 151: Dapagliflozin/Metformin Revenue ($US), by Country, 2007 - 2012
- Exhibit 152: Summary of Bristol - Myers Squibb' s Type 2 Diabetes Product
Portfolio
- Exhibit 153: Summary of Competitor' s Type 2 Diabetes Product Portfolio
- Exhibit 154: Metaglidasen Revenue ($US), 2007 - 2012
- Exhibit 155: Metaglidasen Revenue ($US), by Country, 2007 - 2012
- Exhibit 156: Summary of Dr. Reddy' s Laboratories' Type 2 Diabetes Product
Portfolio
- Exhibit 157: Balaglitazone Revenue ($US), 2007 - 2012
- Exhibit 158: Balaglitazone Revenue ($US), by Country, 2007 - 2012
- Exhibit 159: Summary of Daiichi Sankyo' s Type 2 Diabetes Product Portfolio
- Exhibit 160: Rivoglitazone Revenue ($US), 2007 - 2012
- Exhibit 161: Rivoglitazone Revenue ($US), by Country, 2007 - 2012
- Exhibit 162: Summary of Sanofi - Aventis' s Type 2 Diabetes Product
Portfolio
- Exhibit 163: Lixisenatide Revenue ($US), 2007 - 2012
- Exhibit 164: Lixisenatide Revenue ($US), by Country, 2007 - 2012
- Exhibit 165: Summary of Competitor' s Type 2 Diabetes Product Portfolio
- Exhibit 166: Ondero Revenue ($US), 2007 - 2012
- Exhibit 167: Ondero Revenue ($US), by Country, 2007 - 2012
- Exhibit 168: Summary of Isis Pharmaceuticals' Type 2 Diabetes Product
Portfolio
- Exhibit 169: ISIS - 113715 Revenue ($US), 2007 - 2012
- Exhibit 170: ISIS - 113715 Revenue ($US), by Country, 2007 - 2012
- Exhibit 171: Type 2 Diabetes Market ($US), Major Markets, 2007 - 2012
(Tabular Format)
- Exhibit 172: Type 2 Diabetes Market ($US), Major Markets, 2007 - 2012
(Graphical Format)
- Exhibit 173: Timeline of Key Events, Type 2 Diabetes Market, 2007 - 2012
- Exhibit 174: U.S. Market Dynamics for Branded Type 2 Diabetes Drugs, by
Drug Class, 2007 - 2012
- Exhibit 175: European Market Dynamics for Branded Type 2 Diabetes Drugs,
by Drug Class, 2007 - 2012
- Exhibit 176: Japanese Market Dynamics for Branded Type 2 Diabetes Drugs,
by Drug Class, 2007 - 2012
- Exhibit 177: Branded Type 2 Diabetes Market ($US), by Country, 2007 - 2012
- Exhibit 178: Type 2 Diabetes Market ($US), by Drug Class, 2007 - 2012
- Exhibit 179: Type 2 Diabetes Market, by Drug Class, as a Percentage of
Total, 2007 and 2012
- Exhibit 180: PPAR - Gamma Agonist Market ($US), by Country, 2007 - 2012
- Exhibit 181: DPP - IV Inhibitor Market ($US), by Country, 2007 - 2012
- Exhibit 182: Meglitinide Market ($US), by Country, 2007 - 2012
- Exhibit 183: Fixed - Dose Combination Market ($US), by Country, 2007 - 2012
- Exhibit 184: Amylin Market ($US), by Country, 2007 - 2012
- Exhibit 185: Alpha Glucosidase Inhibitors Market ($US), by Country, 2007 -
2012
- Exhibit 186: Insulin Sensitizers Market ($US), by Country, 2007 - 2012
- Exhibit 187: SGLT2 Inhibitors Market ($US), by Country, 2007 - 2012
- Exhibit 188: Type 2 Diabetes Market ($US), by Brand, 2007 - 2012
- Exhibit 189: Branded Type 2 Diabetes Market ($US), by Brand, 2007 - 2012
- Exhibit 190: Branded Type 2 Diabetes Market ($US), by Company, 2007 - 2012
- Exhibit 191: Prevalent and Diagnosed Type 2 Diabetes Cases, Major Markets,
2007 - 2012
- Exhibit 192: Diagnosed Type 2 Diabetes Cases, by Country, Major Markets,
2007 - 2012
- Exhibit 193: Prevalent and Diagnosed Type 2 Diabetes Cases, by Country,
Major Markets, 2007 - 2012
- Exhibit 194: Adjusted Price of Actos ($US), 2007 - 2012
- Exhibit 195: Adjusted Price of Avandia ($US), 2007 - 2012
- Exhibit 196: Adjusted Price of Prandin ($US), 2007 - 2012
- Exhibit 197: Adjusted Price of Starlix ($US), 2007 - 2012
- Exhibit 198: Adjusted Price of Actoplus Met ($US), 2007 - 2012
- Exhibit 199: Adjusted Price of Avandaryl ($US), 2007 - 2012
- Exhibit 200: Adjusted Price of Avandamet ($US), 2007 - 2012
- Exhibit 201: Adjusted Price of Precose ($US), 2007 - 2012
- Exhibit 202: Adjusted Price of Glyset ($US), 2007 - 2012
- Exhibit 203: Licensing Deals and Revenue Allocation
|
Related Report
|
View Cart
